Skinvisible SKVI
OTC SKVI
$0.18 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

Skinvisible (SKVI) Net Income Attributable to Noncontrolling Interests (2017)

Updated

Skinvisible (SKVI) recorded Income from Non-Controlling Interests of -$280.00 in Q3 2017.

Analysis

Skinvisible (SKVI) Net Income Attributable to Noncontrolling Interests (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Skinvisible 972,691.78 963,669.78 5,000.00 -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2017 -280.00
API Access

Skinvisible Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=SKVI&period=max&api_key=YOUR_API_KEY